← back to search

Jacqueline McBride

University of York · GB
Area of research
Genetics · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Medicine, Internal medicine, Ulcerative colitis, Placebo, Gastroenterology, and Antibody.
h-index
citations
569
works
9
NIH funding
primary concept
email

Recent publications

P0063 Colonic imaging mass cytometry and tissue transcriptomics reveal B cell and plasma cell modulation as a key immune feature of response to the anti-integrin therapy etrolizumab in ulcerative colitis
Journal of Crohn s and Colitis 2026cited by 0position: middledoi
Engineering a protease-stable, oral single-domain antibody to inhibit IL-23 signaling
Proceedings of the National Academy of Sciences 2025cited by 8position: middledoi
Gut Microbial Species and Endotypes Associate with Remission in Ulcerative Colitis Patients Treated with Anti-TNF or Anti-integrin Therapy
Journal of Crohn s and Colitis 2024cited by 11position: middledoi
A Randomized Phase II Study of Efmarodocokin Alfa, an interleukin-22 Agonist, Versus Vedolizumab in Patients With Ulcerative Colitis
Clinical Gastroenterology and Hepatology 2024cited by 10position: middledoi
Local Pentraxin-2 Deficit Is a Feature of Intestinal Fibrosis in Crohn’s Disease
Digestive Diseases and Sciences 2023cited by 2position: middledoi
Dual targeting of lymphocyte homing and retention through α4β7 and αEβ7 inhibition in inflammatory bowel disease
Cell Reports Medicine 2021cited by 48position: middledoi
Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma
Blood Cancer Journal 2019cited by 59position: middledoi
Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients
Antimicrobial Agents and Chemotherapy 2016cited by 94position: middledoi
A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)
Annals of the Rheumatic Diseases 2015cited by 337position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Mary Keir · California Institute for Regenerative Medicine3 papers (2021–2024)Alexis Scherl · Rockefeller University2 papers (2021–2025)Tangsheng Yi · Howard Hughes Medical Institute2 papers (2021–2025)Anita Patel · Imperial College London1 papers (2016–2016)Rong Deng · Sun Yat-sen University Cancer Center1 papers (2016–2016) · 1 papers (2025–2025) · 1 papers (2026–2026)Jordan S. Mar · Acentech (United States)1 papers (2024–2024)Eric W. Humke · Stanford University1 papers (2019–2019)Vanitha Ramakrishnan · University of York1 papers (2019–2019)Jorge A. Tavel · National Institute of Allergy and Infectious Diseases1 papers (2016–2016)Iny Jhun · Palo Alto University1 papers (2023–2023)Julián Panés · Instituto de Salud Carlos III1 papers (2024–2024)Seema Singhal · All India Institute of Medical Sciences1 papers (2019–2019)Ryan Ichikawa · Acentech (United States)1 papers (2021–2021)Kirsten Mundt · Novartis (Switzerland)1 papers (2019–2019) · 1 papers (2019–2019) · 1 papers (2021–2021)Sikander Ailawadhi · Nemours Children's Clinic1 papers (2019–2019)Silvio Danese · Io Therapeutics (United States)1 papers (2024–2024)